Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - NIAID - Additional Information (Details)

v3.19.3
Licensing and Other Arrangements - NIAID - Additional Information (Details) - USD ($)
$ in Thousands
 9 Months Ended 12 Months Ended
Sep. 30, 2019
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Deferred revenue balance classified as contract liability due to government adjustment $ 798   $ 798 [1]  
National Institute of Allergy and Infectious Diseases "NIAID" [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contract liabilities 800   $ 800  
National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 2 [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total contract amount awarded $ 64,800      
Contracts revenue wrote off   $ 400    
National Institute of Allergy and Infectious Diseases "NIAID" [Member] | Arrangement with Governmental Agency 3 [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Contractual term 3 years      
Accounts receivable       $ 400
Deferred revenue balance classified as contract liability due to government adjustment       $ 800
[1] The consolidated balance sheet as of December 31, 2018 has been derived from the audited consolidated financial statements as of that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.